Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints Rob Gallo as head of corporate communications, Europe and Canada

Will lead efforts to combine communications efforts in two regions

Rob Gallo - TakedaJapan-based Takeda Pharmaceuticals has promoted its interim head of corporate communications for Europe Rob Gallo to a permanent role that also covers Canada.

Gallo had been in his interim position since 2010, overseeing Europe-wide media campaigns, and will now be based at Takeda's regional headquarters in Zurich, Switzerland.

His new responsibilities will include unifying local communication teams as Takeda prepares to combine its Canadian and European businesses into a single Takeda subsidiary, ensuring communication aligns to the company's new strategic model as well as preparing teams for the launch of several products.

Gallo said: “I am delighted to be joining Takeda permanently to help deliver corporate objectives in what is a very exciting stage of the company's development.”

Before joining Takeda, Gallo was a director of Operandi Partners, a corporate communications and issues management consultancy based in London. 

In addition to his pharmaceutical experience, he has also held senior communications posts across a range of FMCG companies in the UK, Italy and Australia.

13th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Watermeadow Medical US

Watermeadow Medical is an award-winning, international agency with offices in Oxford and Manchester, UK and New York, USA. ....

Latest intelligence

UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...
Online Physician Communities
How can pharma innovate in child and TYA cancer?
by Dr Tim Ringrose, M3 (EU)...